MHMasashi Honda

Masashi Honda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Masashi Honda has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Atsushi Takenaka

    Tottori Univ, Dept Urol, Fac Med, 36-1 Nishi, Yonago, Tottori 6838504, Japan

    4 shared publications
  • Katsuya Hikita

    Tottori Univ, Dept Urol, Fac Med, 36-1 Nishi, Yonago, Tottori 6838504, Japan

    4 shared publications
  • Bunya Kawamoto

    A Department of Urology , Tottori University Faculty of Medicine , Yonago , Japan

    3 shared publications
  • Shuichi Morizane

    Tottori Univ, Dept Urol, Fac Med, 36-1 Nishi, Yonago, Tottori 6838504, Japan

    3 shared publications
  • Kuniyasu Muraoka

    A Department of Urology , Tottori University Faculty of Medicine , Yonago , Japan

    2 shared publications
  • Takehiro Sejima

    A Department of Urology , Tottori University Faculty of Medicine , Yonago , Japan

    2 shared publications

Latest Publications

  • Open Access

    Potential role of ghrelin on the micturition reflex in rats

    by Masashi Honda, Ryutaro Shimizu, Ryoma Nishikawa, Shogo Teraoka, Panagiota Tsounapi, Yusuke Kimura, Shuichi Morizane, Katsuya Hikita, Atsushi Takenaka

    The Central European Journal of Urology is an open access quarterly-issued journal, which provides a forum for the presentation of original clinical, experimental and other research studies...

  • Impact of postoperative phosphodiesterase type 5 inhibitor treatment on lower urinary tract symptoms after robot-assisted radical prostatectomy: a longitudinal study

    by Masashi Honda, Bunya Kawamoto, Shuichi Morizane, Katsuya Hikita, Kuniyasu Muraoka, Takehiro Sejima, Atsushi Takenaka

    Objective: This study aimed to assess the role of tadalafil, a phosphodiesterase type 5 inhibitor (PDE5-I), in recovery of lower urinary tract symptoms (LUTS) after robot-assisted radical prostatectomy (RARP). Materials and methods: All patients treated with RARP between October 2010 and August 2013 were enrolled in this retrospective study on prospectively collected data. Patients were retrospectively divided into groups according to postoperative treatment: patients taking tadalafil twice weekly from 1 month to 6 months after RARP, and patients not taking tadalafil. The International Prostate Symptom Score (IPSS), the Overactive Bladder Symptom Score (OABSS) and urinary continence (UC) were assessed preoperatively (2 days before RARP) and at 1, 3, 6, 9 and 12 months after RARP. Results: There was no difference in the overall IPSS score between the groups. At 6 and 9 months, the IPSS storage symptom scores were significantly lower in patients taking tadalafil than in patients not taking tadalafil. In patients with overactive bladder (OAB) before RARP (n = 22), no differences in the total scores of OABSS were seen between patients taking tadalafil and patients not taking tadalafil. On the other hand, in non-OAB patients before RARP (n = 68), at 3, 6 and 9 months, the total scores of OABSS were significantly lower in patients taking tadalafil than in patients not taking tadalafil. No differences in UC rates after surgery were seen between the groups. Conclusion: Postoperative tadalafil treatment may be temporarily effective for the recovery of the IPSS storage symptom scores and OABSS.


  • A prognostic model for predicting urinary incontinence after robot‐assisted radical prostatectomy

    by Masashi Honda, Bunya Kawamoto, Shuichi Morizane, Katsuya Hikita, Kuniyasu Muraoka, Takehiro Sejima, Atsushi Takenaka

    Background: The aim of this study is to develop a novel prognostic model for estimating the risk of postoperative urinary incontinence (UI) after robot‐assisted radical prostatectomy (RARP).Methods: Participants comprised 131 men who underwent RARP at our hospital from 2011 to 2013. Cox regression analyses were performed to evaluate associations between UI and preoperative factors including filling cystometry and pressure‐flow study results and magnetic resonance imaging.Results: Logistic regression analyses revealed significant associations between membranous urethral length or levator thickness and UI at 3 and 6 months. Stratification produced high (membranous urethral length < 9.5 mm or levator thickness < 9.0 mm) and low (membranous urethral length ≥ 9.5 mm and levator thickness ≥ 9.0 mm) UI risk groups. These inter‐group differences in UI rate were significant.Conclusions: We developed a novel prognostic model based on preoperative patient data that can be used for patient counselling.


  • Open Access

    Botulinum toxin type A injection for neurogenic detrusor overactivity: Clinical outcome in Japanese patients

    by Katsuya Hikita, Masashi Honda, Bunya Kawamoto, Tsounapi Panagiota, Seiya Inoue, Nobuyuki Hinata, Kuniyasu Muraoka, Atsushi Takenaka

    Objectives To report our experience with intravesical injection of botulinum toxin type A into the detrusor muscle of patients with neurogenic detrusor overactivity secondary to suprasacral spinal cord lesions or multiple sclerosis. Methods Between January 2003 and March 2011, 11 patients (aged 23–75 years) were treated with 40 injections of botulinum toxin type A 300 U. The patients were followed up for 4, 8 and 12 weeks after treatment. The King's Health Questionnaire was administered and cystometric studies were carried out at baseline and 8 weeks after treatment. Results A total of six women and five men were treated. Analysis of the King's Health Questionnaire showed a significant improvement in eight of the nine domain scores at 8 weeks from baseline. On cystometric studies, the mean maximum cystometric capacity increased significantly in all patients at 8 weeks from baseline (P < 0.001). Bladder compliance also increased significantly (P < 0.001). The number of urinary incontinence episodes per day improved significantly from baseline after injection (4 weeks, P < 0.001; 8 weeks, P < 0.001; 12 weeks, P < 0.001). Lack of efficacy appeared 7.15 ± 3.4 months after treatment. Conclusions Injection of botulinum toxin type A into the detrusor muscle of patients with neurogenic detrusor overactivity secondary to suprasacral spinal cord lesions or multiple sclerosis consistently improves bladder control and quality of life.